About Nyxoah

Obstructive sleep apnea (OSA) is the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. This sleep disorder is characterized by recurrent episodes of apneas or hypopneas during sleep.

More than 930 millions of individuals are estimated to suffer from obstructive sleep apnea.

CPAP therapy is usually the first treatment option recommended to patients with obstructive sleep apnea (OSA).
However, some patients are uncomfortable about using the rather cumbersome CPAP device or may be concerned about CPAP’s potential side effects or downsides.
As a result, adherence to CPAP therapy remains problematic, and many people search for other treatment options.

Nyxoah Reinvents Obstructive Sleep Apnea Treatment With Genio

Nyxoah’s lead solution, Genio, uses hypoglossal nerve stimulation (HGNS) to treat obstructive sleep apnea.

This technology is centered on stimulating the hypoglossal nerve, which activates the genioglossus muscle resulting in a forward protrusion of the tongue. HGNS therapies have proven to be a safe and effective treatment for those suffering from moderate to severe obstructive sleep apnea.

Unlike positive airway pressure (PAP), Genio does not involve the wearing of a mask. As such, it is a true alternative for people who cannot tolerate, have failed or refused CPAP therapy.

Following the successful completion of the BLAST OSA study ^*, the Genio system received its European CE Mark in 2019.

Following the positive outcomes of the BETTER SLEEP study, Nyxoah also received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy.

Additionally, Nyxoah is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.